Access to COVID-19 Tools Accelerator

The Global Fund is a founding partner of the Access to COVID-19 Tools (ACT) Accelerator, a global collaboration of organizations and governments working to accelerate development, production and equitable access to new COVID-19 technologies.

As part of the ACT Accelerator:

  • Diagnostics partnership: We are a co-convener with the Foundation for Innovative New Diagnostics, FIND
  • Therapeutics partnership: We are the workstream co-lead for procurement and deployment
  • Health systems connector: We are a co-convener with the World Bank

Raising support

The European Commission hosted a Coronavirus Global Response pledging event on 4 May in support of the ACT Accelerator, raising more than €9.8 billion. Catharina Boehme, Chief Executive Director of FIND, spoke on behalf of the Diagnostics Partnership and her co-lead Peter Sands, Executive Director of the Global Fund, calling on the global community and political leaders to support this landmark collaboration and for donors to urgently provide the necessary resources to produce and distribute diagnostics tests.

Building on the success of the May pledging event, Global Citizen and the European Commission launched the Global Goal: Unite for Our Future campaign aimed at ensuring that everyone, everywhere in the world, has access to COVID-19 tests, treatments and vaccines. On 27 June, a summit and concert aired in more than 180 countries and streamed globally across major platforms. Raising a total of US$6.9 billion in grants and loans from governments, the private sector and foundations, the summit combined entertainment and policy as a pathway to outline the ACT Accelerator call to action and investment case for developing and equitably allocating tests, treatments and vaccines to the people who need them. The investment case provides a consolidated overview of the accelerator, its goals and the investments that partners have calculated are required to carry out its mission, which are also separately elaborated in the individual partnership investment cases.

In addition to raising additional resources for the Global Fund COVID-19 Response Mechanism – which aims to support the COVID-19 emergency response, shore up health systems, protect health workers, and help countries adapt HIV, TB and malaria programs – we are committed to working with the ACT Accelerator partners to secure the needed funding for the development and equitable deployment of new and existing tools to fight COVID-19.

Diagnostics partnership

Without mass testing, which relies on availability of high-performing, rapid tests, COVID-19 will continue to spread. Innovation and scale up of these tests must be accelerated for deployment in all countries. For low- and middle-income countries, this investment would contribute to saving 9 million lives, and strengthen health systems to overcome the COVID-19 pandemic.

An investment of US$6 billion is required to harness innovation and secure access to vital diagnostic tests over the next 12 months for low- and middle-income countries.

US$2 billion of this is required immediately to expedite development, manufacturing and scale-up of the rapid tests that will enable mass testing to be introduced globally – as well as procurement of tests to fill critical short-term gaps in low-income countries.

With WHO leading on product allocation, the Global Fund will work with FIND and other partners, including the research industry, private sector, foundations, government donors, civil society, regulators and international organizations to support the procurement and deployment of diagnostic tests in low- and middle-income countries unable to shoulder such costs on their own and strengthen health systems and build country capacity and preparedness for rapid and effective test implementation.

The investment case is available for download:

Therapeutics partnership

There is an urgent need to develop effective therapeutics for COVID-19. Therapeutics are essential to reduce morbidity and mortality from the pandemic and mitigate the long-term damage to people’s health.

To accelerate development and evaluation of new and repurposed drugs to treat patients, a global investment of at least US$11.6 billion over the coming 12 months is necessary. This includes international financial assistance to provide US$7.2 billion, of which US$3.8 billion is needed immediately. Such an investment will facilitate the coordination of a number of individual efforts to ensure investments in production capacity to manage the demand, as well as procurement and supply chain management of effective therapeutics in low- and middle-income countries.

The Therapeutics Partnership of the ACT Accelerator is co-convened by the Wellcome Trust, on behalf of the Therapeutics Accelerator, and Unitaid. Within the partnership, the Global Fund leads the workstream on adequate procurement and deployment in all countries.

The investment case is available for download:

  • Therapeutics Partnership Investment Case
    download in English